Cadogan Energy Solutions Plc
("Cadogan" or the "Company")
Director Dealings
Cadogan Energy Solutions plc ("Cadogan" or the "Company") today announces that its Non-Executive Director, Mr. Michel Meeus, has purchased on 1 June 2026 a total of 412,500 ordinary shares of £0.03 each, in the capital of the Company, at a price of £0.04 each.
Following this transaction, Mr Michel Meeus holds in total 16,236,151 shares representing 6.4% of the Company.
About
Cadogan is an independent, energy company, which operates an exploration and production license in Western Ukraine, conducts gas trading operations, and provides services to E&P companies. The aim of the Company is to be a diversified energy group making investments offering energy solutions and alternative services with a lower environmental impact.
For further information, please contact:
Cadogan Energy Solutions plc
Fady Khallouf Chief Executive Officer f.khallouf@cadogan-es.com
Ben Harber Company Secretary +44 0207 264 4366
| 1. | Details of PDMR/ person closely associated with them (`PCA') | |
| a) | Name | Michel Meeus |
| 2. | Reason for the notification | |
| a) | Position/status | Non-Executive Director |
| b) | Initial notification / Amendment | Initial notification of sale of shares |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Cadogan Energy Solutions plc |
| b) | LEI | 213800JIBKL29FAK1213 |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| Description of the financial instrument, type of instrumentIdentification code | Ordinary shares of 3 pence eachGB00B12WC938 | |
| b) | Nature of the transaction | Purchase of ordinary shares |
| c) | Price(s) and volume(s) | Price(s) Volume(s)£0.04 412,500 |
Aggregated information
|
412,500£0.04 | |
| e) | Date of the transaction | 1 June 2026 |
| f) | Place of the transaction | OTC |